

Special Issue

Microbiome-Based Interventions in Cancer Immunotherapy

Message from the Guest Editor

This Special Issue aims to gather novel data or perspectives in the area of oncomicrobiome and how microbiome-based strategies can be used to 1) select potential responders to immunotherapy, 2) modulate patients' response to these drugs, and 3) prevent toxicity in patients receiving immunotherapy.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

Role of microbiome in systemic and local cancer treatments;

The effect of the gut and tumor microbiome on response to immunotherapy with checkpoint inhibitors or adoptive cell therapy;

The role of microbiome on inducing or preventing immune-related toxicities from immunotherapy;

Mechanisms of immune modulation by gut microbiome or their products;

Microbiome-based biomarker strategies for patients receiving cancer immunotherapy;

Microbiome-based combination therapies in the area of cancer immunotherapy.

Guest Editor

Dr. Saman Maleki Vareki

1. Department of Pathology and Laboratory Medicine, University of Western Ontario, London, ON N6A 3K7, Canada
2. London Regional Cancer Program, Lawson Health Research Institute, London, ON N6A 5W9, Canada

Deadline for manuscript submissions

closed (30 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/117597

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)